[Correspondence] Mass azithromycin distributions: balancing childhood mortality and antimicrobial resistance – Authors' reply

We thank Thomas M Lietman and colleagues for the opportunity to clarify the robustness of our methodological approach and aspects of pneumococcal transmission and antimicrobial resistance (AMR) biology not considered in their assessment. WHO conditionally recommends azithromycin mass drug administration (MDA) as a potentially life-saving intervention in vulnerable populations, provided that AMR is closely monitored.1